We produce institutional quality equity research on small/midcap healthcare and life sciences companies, making it available to all investors wherever they are based. Our goal is to bring exciting investment ideas to investors, and to assist companies in achieving their objectives.
9
Research Clients
245
Reports published
10k+
Readers in database
Continued delivery by @RedxPharma in H121. Cash of £39.9m supports R&D plans, & runway thru 2022 covers key catalysts, ie Phase I data & Phase II starts for the 2 wholly-owned clinical assets: RXC004 (#oncology) & RXC007 (#fibrosis). For more on $REDX see: https://www.trinitydelta.org/companies/redx-pharma/
Our #ANGLE initiation covers the gathering commercial momentum of its @Parsortix #LiquidBiopsy platform: new services labs support its pharma services and LDT businesses, w/ potential H221 FDA product clearance opening larger opportunities. $AGL https://www.trinitydelta.org/companies/angle/
The partner of choice for non-viral cell delivery & engineering, @MaxCyte_info, shld see FY21 revenue growth with new deals & rising partner pipeline visibility, as it invests in several initiatives to accelerate growth. For our post-FY20 $MXCT.L note see: https://www.trinitydelta.org/company-pages/
$100m PIPE (at $30.5/ADS, 7% premium) from Baring Private Equity Asia gives @hutchmed additional funds to progress its in-house pipeline (8-10 registration/ registration-intent trials to start in 2021) & build China/global commercial infrastructure. $HCM https://www.trinitydelta.org/companies/chi-med/
Oversubscribed €6.6m rights issue indicates tangible support for @NexstimOyj's growth strategy. New monies will fund exploration of the NBT @SmartfocusTMS platform with accelerated protocols in severe #depression & support several near/mid-term goals. https://www.trinitydelta.org/companies/nexstim/
Proven discovery/R&D expertise underpins a sustainable pipeline, supporting @hutchmed's transition into a global biopharma. Our $HCM Outlook note covers progress to date, plans for pivotal trial starts, & new product launches in China and global markets: https://www.trinitydelta.org/companies/chi-med/
Please sign up here to be added to our distribution database
';